Skip to main content
. Author manuscript; available in PMC: 2010 Mar 17.
Published in final edited form as: Oncogene. 2009 Jul 13;28(37):3286–3295. doi: 10.1038/onc.2009.187

5.

5

The therapeutic gene, BikDD driven by Survivin-VISA promoter inhibited tumor growth and prolonged survival time than that driven by CMV promoter in H1299-Luc lung cancer orthotopic xenograft models. (A) SCID mice with intrathoracic injection of H1299-Luc lung cancer cells were intravenously injected with 25 µg of liposomal plasmid DNA. Arrows indicate the therapy time points. The photon signals were quantified with Xenogen’s living imaging system to reflect the tumor size. Error bars indicate SEM. (B) Kaplan-Meier survival analysis was performed. The mean survival time is 42±2, 53±6, and 60±5 days in Ctrl, CMV-BikDD, and SV-BikDD groups, respectively. (C) SCID mice with intravenous injection of H1299-Luc lung cancer cells were treated with 25 µg of liposomal plasmid DNA as panel A. Each group has 10 mice. The survival curve was presented in Kaplan-Meier survival analysis. The mean survival time is 57±5, 73±5, and 78±3 days in Ctrl, CMV-BikDD, and SV-BikDD groups, respectively. * indicated p value < 0.05.